机构:[1]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou,Guangdong 510280, China南方医科大学珠江医院[2]Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China[3]Institute of Hematology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China华中科技大学同济医学院附属协和医院[4]Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing 100853, China[5]Center for Bone Marrow Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China浙江大学医学院附属第一医院[6]Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032,China[7]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Division of Pediatric Blood Disease Center, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China[8]Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China四川大学华西医院[9]Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221006, China[10]Department of Hematology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[11]Department of Hematology, Changhai Hospital, The Naval Medical University, Shanghai 210000, China[12]Department of Hematology, Tianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, Tianjin 300192, China[13]Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation Research Unit of Key Technique for Diagnosis and Treatments of Haematologic Malignancies, Chinese Academt of Medical Sciences, Peking University, Beijing 100044, China[14]Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China[15]Harbin Institute of Hematology and Cancer, Harbin, Heilongjiang 150001, China[16]Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
This work was supported by funds from the National
Natural Science Foundation of China (Nos. 82270233,
81830004, and 82070168), National Natural Science
Foundation of China Youth Science Foundation Project
(No. 82200246), Translational Research Grant of
NCRCH (No. 2020ZKZC04), National Key R&D Program
of China (No. 2021YFA1100800) and Shanghai
Municipal Health Commission (No. 2020CXJQ02).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
无
最新[2023]版:
大类|3 区医学
小类|3 区医学:内科
第一作者:
第一作者机构:[1]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou,Guangdong 510280, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou,Guangdong 510280, China[2]Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China[4]Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing 100853, China[16]Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.[*1]Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China[*2]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China[*3]Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing 100853, China[*4]Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China
推荐引用方式(GB/T 7714):
Tu Sanfang,Li Ping,Mei Heng,et al.Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma[J].Chinese Medical Journal.2024,doi:10.1097/CM9.0000000000003085.
APA:
Tu Sanfang,Li Ping,Mei Heng,Liu Yang,Hu Yongxian...&Liang Aibin.(2024).Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma.Chinese Medical Journal,,
MLA:
Tu Sanfang,et al."Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma".Chinese Medical Journal .(2024)